Breast cancer drug Perjeta has been approved by England’s healthcare cost effectiveness watchdog NICE, a breakthrough achieved after Roche offered a substantial price cut. The decision has been ...

an investigational biosimilar of Perjeta ® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant ...

The Perjeta-based regimen should be administered for one year as part of a complete regimen for eBC and regardless of the timing of surgery. HER2-positive breast cancer affects almost 100,000 ...

an investigational biosimilar of Perjeta ® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant ...

Risks and uncertainties include, but are not limited to, an inability to market HLX11, an investigational biosimilar of Perjeta® (pertuzumab), in Europe, an inability to execute on Organon’s ...